Implementing Outcomes‐Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel
Facey KM, Espin J, Kent E, Link A, Nicod E, O'Leary A, Xoxi E, van de Vijver I, Zaremba A, Benisheva T, Vagoras A, Upadhyaya S.
July 2021
Implementing outcomes-based managed entry agreements for rare disease treatments: nusinersen and tisagenlecleucel. Pharmacoeconomics. 2021 Sep;39(9):1021-44.